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Abstract
Context—Lung cancer is one of the most common cancers affecting both men and women and is 
associated with high symptom burden and psychological distress. Lung cancer patients’ family 
caregivers also show high rates of distress. However, few interventions have been tested to 
alleviate significant problems of this population.
Objectives—This study examined the preliminary efficacy of telephone-based symptom 
management (TSM) for symptomatic lung cancer patients and their family caregivers.
Methods—Symptomatic lung cancer patients and caregivers (N=106 dyads) were randomly 
assigned to 4 sessions of TSM consisting of cognitive-behavioral and emotion-focused therapy or 
an education/support condition. Patients completed measures of physical and psychological 
symptoms, self-efficacy for managing symptoms, and perceived social constraints from the 
caregiver; caregivers completed measures of psychological symptoms, self-efficacy for helping the 
patient manage symptoms and managing their own emotions, perceived social constraints from the 
patient, and caregiving burden.
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Results—No significant group differences were found for all patient outcomes and caregiver 
self-efficacy for helping the patient manage symptoms and caregiving burden at 2 and 6-weeks 
post-intervention. Small effects in favor of TSM were found regarding caregiver self-efficacy for 
managing their own emotions and perceived social constraints from the patient. Study outcomes 
did not significantly change over time in either group.
Conclusion—Findings suggest that our brief telephone-based psychosocial intervention is not 
efficacious for symptomatic lung cancer patients and their family caregivers. Next steps include 
examining specific intervention components in relation to study outcomes, mechanisms of change, 
and differing intervention doses and modalities.
Keywords
lung cancer; family caregivers; psychosocial interventions; cognitive-behavioral; symptom 
management; distress
Introduction
Lung cancer is one of the most frequently diagnosed cancers and the leading cause of cancer 
deaths in both men and women.1 Most lung cancer patients (85%) have regional or distant 
metastases at diagnosis, contributing to their high rate (80%) of multiple physical and 
psychological symptoms.2–4 Lung cancer patients experience higher rates of anxiety and 
depressive symptoms and breathlessness than other cancer patients.5–7 The most frequent 
and severe symptoms in lung cancer patients include depression, anxiety, pain, fatigue, and 
breathlessness, which contribute to impaired quality of life (QoL).2, 8–11 Greater distress and 
reduced QoL in lung cancer patients have been associated with lower self-efficacy or 
confidence in their ability to manage symptoms and greater social constraints (e.g., 
avoidance, criticism) on cancer-related disclosure.12, 13
Family caregivers’ QoL is also affected.14–18 Up to 50% of family caregivers of lung cancer 
patients experience significant anxiety or depressive symptoms.14, 19–22 Greater caregiver 
distress has been related to greater caregiving burden and lower self-efficacy in assisting the 
patient with symptom management.12, 23 Caregivers of lung cancer patients have reported 
difficulty with caregiving tasks such as providing emotional support and monitoring 
symptoms.24, 25
Clinical practice guidelines for lung cancer have changed to emphasize the early integration 
of standard oncologic and palliative care based on evidence that this may improve QoL and 
possibly survival in advanced lung cancer patients.26–28 Although palliative care services are 
available in many hospitals, patients with lung and other cancers and their caregivers have 
reported high rates of unmet needs for symptom management and psychosocial 
support.29–31 In addition, non-pharmacologic aspects of palliative care have a limited 
evidence base for use with lung cancer patients and caregivers.32–34 To date, cognitive-
behavioral interventions have reduced physical symptom severity in patients with various 
cancers and chronic illnesses35–41 and reduced distress in primarily early-stage cancer 
patients and caregivers.32, 38 Two trials have tested emotion-focused interventions for 
couples coping with cancer and both showed improved relational outcomes.42, 43 Regarding 
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trials specific to lung cancer patients and caregivers, one pilot study found that a telephone-
based dyadic intervention reduced advanced lung cancer patient and caregiver anxiety and 
depressive symptoms and caregiver burden compared to usual care.44 A telephone-based 
trial for early-stage lung cancer patients and caregivers found that both caregiver-assisted 
coping skills training and education/support led to improvement in patient depression, lung 
cancer symptoms, and self-efficacy for symptom control as well as caregiver anxiety and 
self-efficacy for helping the patient manage symptoms.45
The present study tested a novel telephone-based symptom management (TSM) intervention 
with lung cancer patients and caregivers jointly participating. Telephone delivery reduces 
barriers to participation for people with physical impairments. While most prior symptom 
management trials with cancer patient-caregiver dyads have emphasized patient 
care,32, 45–49 TSM has a dual focus on patient and caregiver concerns. The intervention 
involves a blend of evidence-based cognitive-behavioral and emotion-focused 
strategies42, 45, 50–53 to address patient and caregiver anxiety and depressive symptoms and 
patient pain, fatigue, and breathlessness. These primary outcomes were chosen because they 
are amenable to non-pharmacologic intervention and prevalent in this 
population.2, 8–11, 14, 22 The intervention was framed by Social Cognitive Theory, which 
hypothesizes that self-efficacy to implement symptom management strategies will result in 
improved health outcomes.54, 55 The TSM intervention was designed to influence self-
efficacy by encouraging practice of new skills, emphasizing the benefits of practicing the 
skills, and changing maladaptive thoughts. Self-efficacy also may be enhanced as patients 
and caregivers reinforce each other’s practice of the skills.
We enrolled lung cancer patients who met clinical criteria for at least one of five symptoms 
targeted in the intervention (i.e., depressive symptoms, anxiety, pain, fatigue, or 
breathlessness) and their family caregivers. We hypothesized that TSM would lead to 
improved primary outcomes for patients (i.e., reduced depressive symptoms, anxiety, pain, 
fatigue, and breathlessness) and caregivers (i.e., reduced depressive symptoms and anxiety) 
as compared to an education/support condition that controlled for time and attention 
provided to participants. We also hypothesized that TSM would lead to improved secondary 
outcomes for patients (i.e., self-efficacy for symptom management and perceived social 
constraints from the caregiver) and caregivers (i.e., self-efficacy for helping the patient 
manage symptoms and managing their own emotions, perceived social constraints from the 
patient, and caregiving burden) as compared to the education/support condition.
Methods
Participants and Setting
Participants were recruited from the Indiana University Simon Cancer Center, the 
Roudebush VA Medical Center, and Eskenazi Hospital in Indianapolis, IN between March 
2013 and April 2015. All study procedures received institutional review board approval 
(Clinicaltrials.gov number NCT01993550). Patient inclusion requirements were: 1) a 
diagnosis of small-cell or non-small-cell lung cancer, 2) English fluency, 3) at least one 
symptom of moderate severity, defined by validated cutpoints for depressive symptoms 
(Patient Health Questionnaire-2 [PHQ-2] score ≥ 3 on this 0–6 scale);56 anxiety 
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(Generalized Anxiety Disorder two-item scale [GAD-2] score ≥ 3 on this 0–6 scale);57 pain 
(PEG score ≥ 5 on this 0–10 scale);58 fatigue (SF-36 Vitality score ≤ 45 on this 0–100 
scale);59, 60 or breathlessness (Memorial Symptom Assessment Scale [MSAS] shortness-of-
breath severity score ≥ 2 on this 1–4 scale),61 and 4) a consenting family caregiver. Patients 
were excluded from study participation if they: 1) had severe cognitive impairment defined 
as four or more errors on a six-item cognitive screener,62 or 2) were receiving hospice care 
at the time of enrollment.
An authorized study team member reviewed medical records and consulted with oncologists 
to confirm initial patient eligibility. A research assistant approached the patient during an 
oncology clinic visit to describe the study. Interested patients identified their primary family 
caregiver (i.e., the person who provided most of their unpaid, informal care) and completed 
the symptom eligibility screening. With the patient’s written consent, a research assistant 
approached caregivers in clinic or via telephone to obtain informed consent. Eligible 
caregivers were adults (18+ years of age) who were fluent in English and lived with the 
patient or had visited the patient at least twice a week for the past month. At the time of 
enrollment, all participants received a brochure outlining psychosocial services at the study 
site.
Adequate sample size was determined on the basis of group comparisons of anxiety and 
depressive symptoms. An a priori power analysis suggested that a mixed linear model would 
have 80% power to detect a Cohen’s d of 0.63 (P=0.05, two-sided) in a sample of 42 patient-
caregiver dyads, assuming an intraclass correlation coefficient of 0.05.63 This effect size is 
smaller than that found for anxiety and depressive symptoms in a trial comparing a dyadic 
telephone-based psychosocial intervention to usual care for advanced lung cancer patients 
and caregivers.44
Of the 337 potentially eligible lung cancer patients who were approached regarding this 
study, 86 declined to participate, 117 were deemed ineligible, and 134 consented. The most 
common reasons for study refusal were lack of interest, time constraints, and personal stress. 
Most ineligible patients did not meet the symptom criterion for study entry. Of the 134 
patients and 128 caregivers who consented, 50 withdrew before randomization primarily 
because of medical reasons, loss of interest, or an inability to reach them via phone. Thus, 
106 patient-caregiver dyads were included in the current analyses (Fig. 1).
Procedures
All participants completed an individual baseline assessment and then patient-caregiver 
dyads were randomly assigned to one of two conditions: 1) telephone symptom management 
(TSM; n=51 dyads) or 2) an education/support condition (n=55 dyads). Randomization 
assignments were generated by a person who was not a study interviewer or therapist using a 
SAS procedure. Randomization was stratified by patient gender and performance status 
(self-reported Eastern Cooperative Oncology Group scores 0 or 1 vs. ≥2).64, 65 Patients and 
caregivers completed an individual follow-up assessment at 2 weeks and 6 weeks post-
intervention because we were interested in short-term effects of the intervention and two 
weeks matched the time frame of certain measures. Research assistants who were blind to 
study condition conducted all assessments via telephone.
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General Aspects of Treatment Procedures and Therapist Training—Participants 
in both study conditions (TSM and education/support) participated in four weekly 45-minute 
telephone sessions. Both dyad members participated simultaneously via speakerphone, and 
all sessions were audiorecorded. Both study conditions were delivered by licensed clinical 
social workers who were trained by a PhD-level psychologist. Training included didactic 
instruction and role-plays of treatment sessions detailed in manuals. Following the initial 
training, social workers received weekly supervision from the psychologist who reviewed 
53% of audiorecordings for adherence to the study protocol and provided feedback on 
treatment adherence and quality. The average fidelity rating was 97.5%.
Telephone Symptom Management—Participants in this condition received instruction 
in symptom management strategies. Each person was mailed identical handouts detailing 
major points discussed during the sessions and home practice assignments as well as a CD 
with instructions for relaxation exercises. The primary goal of the intervention was to teach 
patients and caregivers various evidence-based cognitive-behavioral and emotion-focused 
strategies for managing anxiety and depressive symptoms, pain, fatigue, and breathlessness. 
All sessions had a dual focus on patient and caregiver concerns. A summary of the 
intervention components appears in Table 1.
During the first session, the social worker introduced the sessions as providing information 
and skills for coping with lung cancer and discussed cancer-related changes that the patient 
and caregiver had experienced. During the four sessions, the patient and caregiver received 
instruction in symptom management strategies, including relaxation exercises, problem-
solving, cognitive restructuring, emotion-focused/self-soothing approaches, communication 
skills, pleasant activity scheduling, and activity pacing. The symptoms endorsed by the 
patient or caregiver were emphasized when presenting the strategies, but all dyads received 
training in the same strategies. Skill practice comprised the majority of each session, and 
dyad members practiced the skills simultaneously (e.g., relaxation) or consecutively (e.g., 
communication). Each session began with a review of the patient’s and caregiver’s practice 
of the skills and ended with a discussion of a home practice assignment. Dyad members 
were encouraged to practice the skills together at home.
Education/Support Condition—The primary goal of this intervention was to direct 
participants to resources for practical and health information and psychosocial services. A 
similar comparison group was used in a prior psychosocial intervention trial with 
gastrointestinal cancer patients and caregivers.43 The therapists were the same as those for 
the TSM condition. Table 1 provides a summary of the intervention components. The 
sessions included the following topics: orientation to the medical center and treatment team, 
the impact of cancer on QoL, resources for health information, psychosocial support, and 
financial concerns, and evaluating health information on the Internet. Each person was 
mailed handouts summarizing the topics for each session and was asked to review them at 
home. Instruction in symptom management strategies did not occur in the education/support 
condition.
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Measures
The primary and secondary outcomes were assessed with validated self-report measures 
used with cancer patients and caregivers.
Primary Outcomes—The Patient Health Questionnaire-8 (PHQ-8)66, 67 and Generalized 
Anxiety Disorder seven-item scale (GAD-7)57 were used to assess patient and caregiver 
depressive and anxiety symptoms, respectively. In addition, the following measures assessed 
patient physical symptoms: 1) the Brief Pain Inventory Short Form consisting of pain 
severity and pain interference subscales;68, 69 2) the Fatigue Symptom Inventory consisting 
of fatigue frequency, severity, and interference subscales;70, 71 and 3) four items from the 
MSAS assessing the frequency and severity of breathlessness as well as distress related to 
breathlessness.61
Secondary Outcomes—A 16-item standard self-efficacy scale modified from the 
arthritis literature was used to assess patients’ perceived ability to manage pain, other 
symptoms, and function.12, 72 A parallel version of this scale was administered to caregivers 
to assess their confidence in their ability to help the patient manage symptoms.12, 72 In 
addition, eight items developed by Kilbourn et al.73 were used to assess caregivers’ self-
efficacy for managing their own emotions. Patients and caregivers also completed the 5-item 
social constraints scale assessing perceived constraints on cancer-related disclosure from the 
other dyad member.74 Finally, the Caregiver Reaction Assessment was used to evaluate 
caregiver burden and included the following subscales: impact on schedule, caregiver’s 
esteem, lack of family support, impact on health, and impact on finances.75
Sociodemographic and Medical Variables—Patients and caregivers reported their 
demographic information and use of mental health services at baseline. Patient medical 
information was obtained via chart review.
Statistical Analyses
Baseline comparisons (Fisher’s exact tests and t-tests) assessed differences between the 
TSM and education/support groups for patients and caregivers separately. Possible gender 
differences were examined. Linear mixed-model repeated measures analyses in SPSS were 
used to examine the preliminary efficacy of TSM. Because these analyses use all available 
data, an intent-to-treat framework was implemented. For outcomes reported by patients and 
caregivers, multilevel modeling for dyadic data was used to account for the non-
independence of data from two members of the same dyad.76, 77 Models included the main 
effects of time, study group, and social role (patient or caregiver) as well as time x group and 
time x group x role interactions. Both time and study group were treated as categorical 
variables in these models, which focuses the analyses on mean differences between groups 
and across time. A significant treatment effect is indicated either by a significant study group 
main effect or a significant time x group interaction. A significant time x group x role 
interaction indicates that the treatment effect differs for patients and caregivers. For outcome 
measures that only patients or caregivers completed, models included main effects of time 
and study group (TSM or education/support) and the time x group interaction. Again, all 
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variables were treated as categorical. Gender was not included in the models because only 
two significant gender differences in outcomes were found (data not shown).
Results
Participant Characteristics
Table 2 presents participant characteristics by study group and group comparisons at 
baseline. About half of the patients (53%) were women, and most caregivers (73%) were 
women. Patients and caregivers were primarily White and had completed an average of 13 
years of education. The median annual household income was over $30,000. Sixty-three 
percent of caregivers were spouses or partners of the patient. No significant baseline 
differences on demographic, medical, or outcome variables were found for patients and 
caregivers randomized to TSM and education/support conditions, with the exception of 
caregiver income.
Primary Outcomes
Results from the mixed model dyadic analyses revealed no main effect of study group or 
time x group effect for anxiety and depressive symptoms (Table 3). However, there was a 
main effect of role on depressive symptoms such that patients, on average, had higher levels 
of depressive symptoms than caregivers. In addition, mixed model analyses showed no main 
effects of study group or time x group effect for patient pain, fatigue, or breathlessness 
(Table 4). There were also no significant main effects of time, indicating that in general 
primary outcome variables did not change on average over the study period.
Secondary Outcomes
Mixed model analyses revealed no main effects of study group or time x group effect for 
patient self-efficacy for symptom management or perceived social constraints from the 
caregiver (Table 4). Regarding secondary outcomes for caregivers, there was a significant 
time x group effect for self-efficacy for managing their own emotions. Means found in Table 
5 showed a small increase in self-efficacy for managing emotions in the TSM group, 
whereas the mean scores for the education/support group showed a slight decline. In 
addition, there was a main effect of study group on caregiver reports of perceived social 
constraints from the patient in favor of TSM (Table 5). Thus, caregivers assigned to TSM 
felt less constrained in discussing the illness with the patient than those assigned to 
education/support. In addition, there were no main effects of study group or time x group 
effect for caregivers’ self-efficacy for managing the patient’s symptoms and all aspects of 
caregiving burden (Table 5).
Discussion
This study is one of the first to examine a dyadic psychosocial intervention for lung cancer 
patients and caregivers and to focus on lung cancer patients with clinically meaningful 
symptoms. Lung cancer patient-caregiver dyads were randomized to four sessions of TSM 
consisting of evidence-based cognitive-behavioral and emotion-focused therapy or four 
sessions of an education/support condition. Compared to the education/support condition, 
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TSM did not result in improved patient and caregiver depressive symptoms or anxiety or 
improved patient pain, fatigue, or breathlessness. In addition, compared to education/
support, TSM did not improve patient self-efficacy for managing their symptoms or 
perceived social constraints from the caregiver. TSM also did not improve caregiver self-
efficacy for assisting the patient with symptom management and caregiving burden. In 
contrast, caregivers assigned to TSM showed better self-efficacy for managing their 
emotions and decreases in perceived social constraints from the patient across follow-ups; 
however, the effect sizes were small. Study outcomes did not significantly change over time 
for either group. Thus, findings do not support the efficacy of our brief telephone-based 
dyadic psychosocial intervention for symptomatic lung cancer patients and caregivers.
The current results are partially consistent with those of prior intervention studies with this 
population.33, 44, 45 For example, Porter and colleagues45 tested 14 telephone sessions of 
caregiver-assisted coping skills training or education/support for early-stage lung cancer 
patients and caregivers and found no differences in psychological distress or symptoms 
between study conditions. Both groups showed improved outcomes following the 
intervention. Conversely, another study found large effects of a 6-session telephone dyadic 
psychosocial intervention on advanced lung cancer patient and caregiver anxiety and 
depressive symptoms and caregiver burden compared to usual care.44 Differences in findings 
across studies may be related to characteristics of the sample, intervention and control 
groups, and assessments.
Several potential explanations for the current findings warrant consideration. First, brief 
cognitive-behavioral and emotion-focused therapy may not be sufficient for addressing the 
high symptom burden and unique challenges of lung cancer patients and caregivers. Similar 
to the general population of lung cancer patients,78 participants were, on average, 
socioeconomically disadvantaged, which may have contributed to suboptimal outcomes and 
barriers to participation. A meta-analysis found limited and inconclusive evidence that non-
pharmacologic interventions impact lung cancer patient outcomes.33 In addition, meta-
analyses have found small effects of couple-based and caregiver-focused interventions on 
psychological outcomes for cancer patients’ caregivers.32, 34 Thus, this study contributes to a 
limited but growing literature suggesting that novel approaches are needed to address the 
significant problems faced by lung cancer patients and caregivers.
Another possible explanation for the current findings is that the brief intervention length and 
telephone delivery lessened the impact of the intervention. As noted earlier, Porter and 
colleagues45 found that lung cancer patients and caregivers assigned to 14 sessions of 
telephone-based coping skills training or education/support showed improved symptom 
outcomes over time. Meta-analytic evidence regarding the effect of intervention dose on 
cancer patient and caregiver outcomes has been mixed.32, 34 One meta-analysis of individual 
and dyadic interventions for cancer patients’ caregivers found that fewer intervention 
sessions were associated with lower levels of depression and caregiving burden.32 Another 
meta-analysis of couple-based interventions did not find an association between the number 
of sessions and cancer patient and caregiver outcomes.34 Further work is needed to 
determine the optimal intervention dose. With respect to intervention modality, there is no 
evidence that telephone delivery is inferior to in-person treatment with respect to cancer 
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patient and caregiver psychological outcomes, but few comparisons of different modalities 
have been conducted.32
Finally, this study did not include a usual care group. This group may have shown worsening 
outcomes over time relative to the TSM and education/support conditions. Three-arm trials 
are needed which compare new interventions to attention control conditions and usual care. 
Such trials would allow for more definitive conclusions regarding the impact of 
interventions.
Results of this study suggest several potential directions for future research. First, examining 
associations between specific intervention components and outcomes will allow researchers 
to develop more efficacious interventions. In addition, understanding the mechanisms 
underlying the effects of interventions will advance the science of symptom management 
and translation of findings to clinical care. A focus on participants with clinically 
meaningful symptoms will enhance the generalizability of findings to those who warrant 
clinical attention. Finally, comparing a dyadic to an individual intervention approach and 
different intervention modalities will clarify the most feasible and effective approach for this 
population.
Limitations of this study should be noted. The sample was primarily Caucasian and was 
recruited from three medical centers in the Midwestern U.S. Thus, the findings may not 
generalize to ethnic minorities and those in other geographic regions. Additionally, 
caregivers were eligible for this study regardless of their distress, which may have reduced 
intervention effects. Furthermore, the attrition rate was 40% at 6 weeks post-intervention, 
which is comparable to attrition rates in other studies with this population.45, 79 Finally, the 
study was underpowered for detecting moderators of the intervention’s effects. Further work 
with larger sample sizes is needed to determine for whom psychosocial interventions are 
most efficacious.
Our findings suggest that symptomatic lung cancer patients and caregivers may require more 
intensive intervention to produce symptom reduction. Next steps include examining the 
effects of specific components of our intervention on outcomes. Identifying the most 
efficacious approaches for symptom reduction and mechanisms underlying their effects is a 
critical issue in palliative care for this large, underserved population.
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Figure 1. 
Study Flow Chart
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Table 1
Summary of Topics Covered in Each Intervention Condition
Telephone Symptom Management Education/Support
• Relaxation:
– Mindfulness exercise
– Imagery
– Pursed lips breathing
• Cognitive restructuring (for unrealistic thoughts)
• Problem-solving (for realistic thoughts about 
controllable situations)
• Self-soothing/emotion-focused approach (for realistic 
thoughts about uncontrollable situations, such as 
thoughts of death and dying)
• Pleasant activities
• Activity pacing
• Communication
• Plan for continued skills practice
• Orientation to the medical center 
and the treatment team
• Psychoeducation regarding the 
impact of cancer on quality of life, 
including physical, social, 
emotional, and cognitive domains 
and roles and activities.
• Resources for addressing financial 
concerns
• Evaluating health information on 
the Internet
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